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The synthesis, structural determination and biological evaluation of 15-membered azalides acy-
lated at the C-3 position are described. 3-Descladinosyl-9a,l1-cyclic carbamate of the 9a-aza-
9a-homoerythromycin A and their 12-O-alkyl derivatives were synthesized via acidic hydro-
lysis of adequate 3-cladinosyl analogues. Protections of 2'-hydroxyl group were performed to
furnish starting compounds for acylation of the C-3-hydroxyl group. After deprotection
various 3-O-acyl derivatives were obtained and their structures confirmed by spectroscopic
methods (IR, MS, NMR). The new compounds were evaluated in vitro against a panel of
Gram-positive and Gram-negative bacteria and their activities compared with those of par-
ent derivatives. The 3-O-acyl derivatives exhibited improved antibacterial activity, but it was






* Author to whom correspondence should be addressed. (E-mail: Andrea.Fajdetic@pliva.hr)
INTRODUCTION
Macrolides are a well-known class of antibacterial agents
that have been used in the treatment of bacterial infec-
tions for many years.1 They are of natural origin, con-
sisting of 12-, 14- and 16-membered lacton ring systems
linked by glycoside bonds with an amino-sugar and neu-
tral sugars. Macrolide antibiotics are lipophilic molecu-
les that inhibit the biosynthesis of proteins binding to the
bacterial ribosome.2
Since the discovery of erythromycin in 1952, many
semisynthetic macrolides have been prepared to improve
antibacterial profiles, acid stability and oral bioavailabi-
lity. From the clinical point of view, the most successful
among them are clarithromycin3–6 and azithromycin.7,8
Azithromycin, a 15-membered macrolide, is character-
ized by its enhanced antibacterial profile and improved
pharmacokinetic properties compared to the 14-member-
ed macrolides, erythromycin and clarithromycin (Figure
1).9 Unfortunately, like erythromycin, both clarithromy-
cin and azithromycin have poor efficacy against some
resistant bacteria.
Cladinose sugar at position 3 was for many years
considered to be an essential component for antibacterial
activity. However, some newly discovered derivatives
without L-cladinose have overcome the known mechani-
sms of resistance. The most successful analogues are
ketolides, macrolides that have a keto functionality at
position 3.10–13 Some other 3-descladinosyl derivatives
(3-O-acyl,14,15 2,3-anhydro16,17 and 3-deoxy derivatives18)
have also shown very high activity against macrolide-re-
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sistant strains. Also, introduction of a cyclic carbamate
group to the 11,12-position of the 14-membered ring has
been successfully used to enhance the molecule’s ability
to bind to the ribosome (Figure 1).19,20
EXPERIMENTAL
IR spectra were recorded in KBr pastilles on a Nicolet
Magna-IR 760 FT-IR spectrometer. Mass spectra were ob-
tained on a Varian-Mat 311A for FAB-MS or Platform LCZ
and LCQ Deca for ESI-MS. 1H and 13C-NMR spectra were
measured with a Varian Unity Inova 600, Bruker Advance
DRX 500 and Bruker Advance DPX 300 spectrometers in
CDCl3 using trimethylsilan as internal standard.
Synthesis of 3-Descladinosyl Derivatives
3-Descladinosyl-9-deoxo-9-dihydro-9a-aza-9a-homoeryth-
romycin A 9a,11-cyclic carbamate 4
To a solution of 9-deoxo-9-dihydro-9a-aza-9a-homoeryth-
romycin A 9a,11-cyclic carbamate 1 (5.18 g) in 96 % ethanol
(150 ml), 0.25 M hydrochloric acid (50 ml) was added and
the reaction mixture was stirred for 48 hours at room tem-
perature. Ethanol was evaporated, and CHCl3 (150 ml) was
added. The pH-value of the mixture was about 1.2. The lay-
ers were separated and the water phase was extracted two
more times with CHCl3. The pH value of water layer was
adjusted to pH 9.5 and then extracted three times with
CHCl3. Combined organic extracts at pH 9.5 were rinsed
with brine, dried over K2CO3 and evaporated, yielding the
product 4 (3.96 g, 93 %).
Under the same conditions, starting from 12-O-methyl-
-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-
cyclic carbamate 2 and 12-O-ethyl-9-deoxo-9-dihydro-9a-
-aza-9a-homoerythromycin A 9a,11-cyclic carbamate 3, the
corresponding 3-descladinosyl-12-O-methyl-9-deoxo-9-di-
hydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carba-
mate 5 and 3-descladinosyl-12-O-methyl-9-deoxo-9-dihy-
dro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate
6 were prepared. Results and physicochemical data of 3-de-
cladonosyl derivatives are given in Table I.
Synthesis of 2'-O-Acetyl-3-Descladinosyl Derivatives
2'-O-Acetyl-3-descladinosyl-9-deoxo-9-dihydro-9a-aza-
9a-homoerythromycin A 9a,11-cyclic carbamate 7
To a solution of 3-descladinosyl-9-deoxo-9-dihydro-9a-aza-
9a-homoerythromycin A 9a,11-cyclic carbamate 4 (3.0 g,
4.98 mmol) in CH2Cl2 (100 ml), NaHCO3 (1.09 g, 13.0
mmol) and acetic acid anhydride (0.62 ml, 6.57 mmol)
were added. The mixture was stirred for 4 hours at room
temperature. Saturated NaHCO3 solution was added into
the reaction mixture, the layers were separated and the aqu-
eous phase was extracted two more times with CH2Cl2.
Combined organic extracts were rinsed with saturated
NaHCO3 solution and water and evaporated, yielding the
product 7 (2.93 g, 91 %)
Applying the same conditions, starting from 3-descla-
dinosyl-12-O-methyl-9-deoxo-9-dihydro-9a-aza-9a-homoe-
rythromycin A 9a,11-cyclic carbamate 5 and 3-descladino-
syl-12-O-ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythro-
mycin A 9a,11-cyclic carbamate 6, the corresponding
2'-O-acetyl-3-descladinosyl-12-O-methyl-9-deoxo-9-dihydro-
302 A. FAJDETI] et al.
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Figure 1. Chemical structures of 11,12-cyclic carbamates of 14-membered macrolides.
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9a-aza-9a-homoerithromycin A 9a,11-cyclic carbamate 8 and
2'-O-acetyl-3-descladinosyl-12-O-ethyl-9-deoxo-9-dihydro-
9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate 9
were prepared respectively. Results and physicochemical
data are given in Table II.
Synthesis of 3-O-(2-Aryl-acetyl)-3-descladinosyl De-
rivatives
3-Descladinosyl-3-O-acetyl-9-deoxo-9-dihydro-9a-aza-
9a-homoerythromycin A 9a,11-cyclic carbamate 10a
To a solution of 2'-O-acetyl-3-descladinosyl-9-deoxo-9-
-dihydro-9a-aza-9a-homoerythromycin A 9a,11-cyclic car-
bamate (7) (0.215 g, 0.321 mmol) in pyridine (6.0 ml,
79.0 mmol), acetic acid anhydride (3.0 ml, 31.6 mmol) was
added and the reaction mixture was stirred at 60 C for 10
hours. The reaction mixture was poured into ice water (50
ml), CH2Cl2 (50 ml) was added and the layers were sepa-
rated. The water layer was extracted two more times with
CH2Cl2. Combined organic extracts were rinsed with satu-
rated aqueous solution of NaHCO3, brine, dried over
K2CO3 and evaporated. The product obtained was dis-
solved in MeOH (50 ml) and the solution was stirred for 24
hours at room temperature. The solvent was evaporated and
the crude product was purified by crystallization from
CH2Cl2 – diethyl ether – n-hexane, yielding product 10a




To a solution of 4-nitrophenylacetic acid (0.644 g, 3.55
mmol) in dry CH2Cl2 (15 ml) TEA (0.504 ml, 3.55 mmol)
was added and the reaction mixture was cooled to 0 C. Pi-
valoyl chloride (0.469 ml, 3.55 mmol) was added and the
reaction mixture was stirred at the same temperature for 30
minutes. Pyridine (0.966 ml, 11.94 mmol) and 2'-O-acetyl-
-3-descladinosyl-9-deoxo-9-dihydro-9a-aza-9a-homoeryth-
romycin A 9a,11-cyclic carbamate 7 (0.70 g, 1.08 mmol)
solution in dry CH2Cl2 (5 ml) were added and the reaction
mixture was stirred at 0 C for 4 hours. Saturated aqueous
solution of NaHCO3 (30 ml) was added and the layers were
separated. The water layer was extracted two more times
with CH2Cl2. Combined organic extracts were rinsed with
brine, dried over K2CO3 and evaporated, yielding 0.70 g of
an oily product. The product obtained was dissolved in
MeOH (50 ml) and the solution was stirred for 24 hours at
room temperature. The solvent was evaporated and the cru-
de product was purified by chromatography on a silica gel
column using the system CH2Cl2 – MeOH – NH4OH (90 :
3 : 0.5). Combining and evaporating chromatographically
homogenous fractions gave the title product, which was
crystallized from CH2Cl2 – diethyl ether – n-hexane, yield-
ing product 10b (0.30 g, 36 %):
Under the same reaction conditions, starting with com-
pound 7, applying 4-fluorophenylacetic acid, 4-methoxy-
phenylacetic acid, phenylpropionic acid and 4-pyridyltio-
acetic acid, the corresponding 3-descladinosyl-
-3-O-(4-fluorophenyl)acetyl-9-deoxo-9-dihydro-9a-aza-9a-
homoerythromycin A 9a,11-cyclic carbamate 10c, 3-des-
cladinosyl-3-O-(4-methoxyphenyl)acetyl-9-deoxo-9-dihydro-
9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate
10d, 3-descladinosyl-3-O-phenylpropionyl-9-deoxo-9-dihydro-
9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate 10e
and 3-descladinosyl-3-O-(pyridylthio)acetyl-9-deoxo-9-dihy-
dro-9a-aza-9a-homoerythromycin A 9a, 11-cyclic carbamate
10f, were prepared, respectively. Similarly, starting with
compound 8 or 9, applying 4-nitrophenylacetic acid, the
corresponding 3-descladinosyl-3-O-(4-nitrophenyl)acetyl-
12-O-methyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromy-
cin A 9a,11-cyclic carbamate 10g and 3-descladinosyl-
3-O-(4-nitrophenyl)acetyl-12-O-ethyl-9-deoxo-9-dihydro-9a-
aza-9a-homoerythromycin A 9a,11-cyclic carbamate 10h





To a solution of 3-descladinosyl-3-O-(4-nitrophenyl)acyl-9-
-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A 9a,11-
-cyclic carbamate 10b (0.20 g, 0.26 mmol) in conc. acetic
acid (25 ml), PtO2H2O (0.12 g, 0.52 mmol) was added and
the reaction mixture was stirred for 2 hours at room temper-
ature under H2 pressure of about 2.25  10
4 torr. The cata-
lyst was filtered, washed and the liquor was evaporated.
The residue was dissolved in CH2Cl2 (30 ml), water (30
ml) was added and the pH value of the mixture was adjust-
304 A. FAJDETI] et al.
Croat. Chem. Acta 78 (2) 301–312 (2005)












7 H 91 C32H56N2O11
(644.81)
645.7 3485, 2973, 2879, 2786, 1747, 1579, 1461, 1417, 1377,
1249, 1168, 1113, 1049, 1006, 947, 899, 810, 770
8 CH3 85 C33H58N2O11
(658.84)
659.4 3442, 2973, 2938, 2879, 2786, 1744, 1460, 1417, 1381,
1250, 1166, 1113, 1050, 1004, 949
9 CH2CH3 98 C34H60N2O11
(672.86)
673.7 3483, 2973, 2878, 2789, 1747, 1578, 1459, 1413, 1380,
1249, 1166, 1113, 1050, 1006, 947, 897, 770
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ed to pH 9.5. The layers were separated and the organic
layer was extracted twice with a saturated aqueous solution
of the NaHCO3. Organic layer was dried over K2CO3 and
evaporated, yielding a crude product, which was purified
by chromatography on a silica gel column using the system
CH2Cl2 – MeOH – NH4OH (90 : 3 : 0.5). Combining and
evaporating chromatographically homogenous fractions gave
the title product, which was crystallized from CH2Cl2 – di-
ethyl ether – n-hexane, yielding product 10i (0.13 g, 68 %).
Applying the same reduction procedure to nitro com-
pounds 10g or 10h, the corresponding 3-descladinosyl-
-3-O-(4-aminophenyl)acetyl-12-O-methyl-9-deoxo-9-dihy-
dro-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate
10j and 3-descladinosyl-3-O-(4-aminophenyl)acetyl-12-O-
ethyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A
9a,11-cyclic carbamate 10k were prepared. Results and
physicochemical data are given in Table IV.
RESULTS AND DISCUSSION
Keeping the structures of new biologically active 14-
membered macrolides with 11,12-carbamate groups, we
assumed that the combination of 3-O-acyl functionality,
the 15-membered scaffold and a 9a,11-cyclic carbamate
group would provide molecules with high antibacterial
activity and the desired pharmacokinetic profile. As
mentioned in the Introduction, those are the structural
functionalities responsible for the high efficacy against
resistant bacteria and improved pharmacokinetic proper-
ties.
In this paper we describe the synthesis, structural
determination and antibacterial activity of novel
3-O-acyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-
homoerythromycin A 9a,11-cyclic carbamate (Figure 2).
308 A. FAJDETI] et al.
Croat. Chem. Acta 78 (2) 301–312 (2005)





























7.14 (H-4'', H-6''), 6.65 (H-3'', H-7''), 5.22
(H-3), 5.14 (H-13), 4.26 (H-11), 4.01 (H-1'),
3.58 (H-5), 3.58 (H-1''a), 3.50 (H-1''b), 3.50
(H-10), 3.43 (H-9a), 3.24 (H-2'), 3.14 (H-5'),
2.77 (H-2), 2.56 (H-3'), 2.47 (H-4), 2.39
/3'N(CH3)2/, 2.37 (H-9b), 2.32 (H-8), 1.91
(H-14a), 1.64 (H-4'a), 1.49 (H-14b), 1.33
(H-7a and 7b), 1.29 (10-CH3), 1.27 (6-CH3),
1.23 (H-4'b), 1.20 (12-CH3), 1.16 (5'-CH3),
1.10 (4-CH3), 0.97 (8-CH3), 0.91 (2-CH3),
0.84 (14-CH3)











7.18 (H-4'', H-6''), 6.72 (H-3'', H-7''), 5.57
(H-13), 5.22 (H-3), 4.24 (H-11), 4.02 (H-1'),
3.58 (H-1''a), 3.56 (H-5), 3.48 (H-10), 3.48
(12-O-Me), 3.44 (H-1''b), 3.44 (H-9a), 3.24
(H-2'), 3.14 (H-5'), 2.73 (H-2), 2.58 (H-3'),
2.45 (H-4), 2.42 (H-9b), 2.40 /3'N(CH3)2/,
2.34 (H-8), 1.75 (H-14a), 1.64 (H-4'a), 1.52
(H-14b), 1.33 (H-7a and 7b), 1.30 (10-CH3),
1.27 (6-CH3), 1.24 (H-4'b), 1.22 (12-CH3),
1.17 (5'-CH3), 1.13 (4-CH3), 1.05 (8-CH3),
0.96 (2-CH3), 0.92 (14-CH3)












7.19 (H-4'', H-6''), 6.74 (H-3'', H-7''), 5.58
(H-13), 5.23 (H-3), 4.23 (H-11), 4.03 (H-1'),
3.98 (12-O-CH2a and CH2b/Et), 3.72 (H-1''a),
3.66 (H-1''b), 3.55 (H-5), 3.50 (H-10), 3.42
(H-9a), 3.24 (H-2'), 3.17 (H-5'), 2.75 (H-2),
2.58 (H-3'), 2.47 (H-4), 2.40 /3'N(CH3)2/, 2.36
(H-8), 2.33 (H-9b), 1.75 (H-14a), 1.65










), 1.13 (4-CH3), 1.11









Starting from 3-O-cladinosyl derivatives 1, 2 and 3 that
had earlier been synthesized in PLIVA,21,22 3-O-descla-
dinosyl derivatives 4, 5 and 6 were prepared by acidic
hydrolysis as shown in Scheme 1. For acylation reac-
tions at position 3, it was necessary to protect the hydro-
xyl group at position C-2'. Treatment of 4, 5 and 6 with
acetic anhydride and NaHCO3 in dichloromethane fur-
nished adequate, selectively protected compounds 7, 8
and 9 (Scheme 1).
Compound 10a was obtained using acetic anhydride
in pyridine at elevated temperature,23 while the 3-O-acyl
derivatives 10b–10h were prepared by acylation of pro-
tected macrolide intermediates 7, 8 and 9 with mixed an-
hydrides (Scheme 2). Applying a similar synthetic route,
some 3-O-acyl-3-O-decladinosyl-8a-aza-8a-homoeryth-
romycins (8a-lactams)24 were previously prepared in our
laboratories.
The reaction conditions depended on the reactivity
of the reagents applied. In some reactions 4-(dimethyl-
amino)pyridine was used as a catalyst. Also, some reac-
tions required higher temperature. Substituents on the
phenyl core influenced the reaction rate as well. In the
case of an electron acceptor group (e.g., nitro group –
10b derivative), the conversion was completed within 4
hours at 0 °C. In contrast, in the presence of an electron
donor group (e.g., fluorine atom – 10c derivative or me-
thoxy group – derivative 10d), complete conversion oc-
curred at room temperature within 20 to 44 hours.
After removal of the acetyl group at the C-2' posi-
tion, the desired 3-O-acyl analogues 10a–10h were ob-
tained.
Amino phenyl derivatives 10i–10k were synthesized
in the next step, starting with the nitro phenyl analogues
10b, 10g and 10h, by hydrogenation in acetic acid using
Pt(IV) oxide as catalyst (Scheme 3).
Structures of the 3-O-descladinosyl derivatives 4–6
were confirmed by the disappearance of the L-cladinose
signals and also by the upfield shifts of the 3-C-atom
signals in the NMR spectra.25
Watching the 1H NMR spectra of the 3-O-acyl de-
rivatives 10a–10k for the 3-H signals, a downfield shift
from 3.8 to 5.2 ppm was observed. The acylation was
supported by a new carbonyl signal at 170 ppm in 13C
NMR spectra. The new signal at 20.5 ppm in the spec-
trum of 3-O-acetyl ester 10a was attributed to the Me
part of the acetyl group. Aromatic derivatives 10b–10k
have characteristic signals in the 1H NMR spectra at
7.51.0 ppm and at 3.50.5 ppm. The 13C NMR spec-
tra also showed new signals, at 150 to 120 ppm (aro-
matic carbon atoms) and at 40 ppm (methylene groups).
The IR spectra of aromatic substituted compounds
10b–10k have two bonds at 1630–1610 cm–1 and 1530 
1510 cm–1, which are characteristic of the stretching vi-
bration of the carbon-carbon bond of the aromatic ring.
Nitrophenyl derivatives 10b, 10g and 10h have two ad-
ditional bonds at 1523 and 1347 cm–1 characteristic of
asymmetric and symmetric stretching vibrations of the
nitro group. The IR spectrum of compound 10a has one
strong bond at 1244 cm–1, which is characteristic of
ACYL DERIVATIVES OF 15-MEMBERED AZALIDES 309











































acetyl esters and is associated with the asymmetric stret-
ching vibration of the carbon-oxygen bond.
Microbiology
The antibacterial activity of the 3-O-acyl derivatives of
the 15-membered 9a,11-cyclic carbamates 10a–10k and
the reference compounds 1–6 were evaluated against a
panel of representative pathogens selected from PLIVA’s
strain collection. Various macrolide-resistant strains were
included in the tests in order to evaluate their potential
for overcoming macrolide resistance. The results are gi-
ven in Table V.
The in vitro antibacterial activities are reported as
minimum inhibitory concentrations (MIC’s), which were
determined by the microdilution method using the
NCCLS recommended methods for dilution antibacterial
tests M7-A5.
Some 3-O-acyl derivatives showed lower activity
against sensitive and efflux resistant S. pneumoniae and
S. pyogenes compared to reference compounds.
310 A. FAJDETI] et al.













































































































































































10b 10h– Scheme 2. a) R2COOH, (CH3)3CCOCl, Et3N, pyri-
dine, 0 °C–45 °C, 4 h–44 h; b) MeOH, r.t., over-
night.
CONCLUSION
A series of 3-O-acyl derivatives of 15-membered macro-
lides were synthesized and evaluated for antibacterial
activity. As assumed, cleavage of L-cladinose abolished
the antibacterial activity. Unfortunately, substitution of
L-cladinose with 3-O-acyl substituents did not improve
activity as we had expected.
To explore new aspects of macrolide antibiotics,
other modifications of 9a,11-cyclic carbamates of 15-
membered macrolides are currently under investigation.
Acknowledgements. – The authors thank Miss Nata{a
Marsi} and Miss Hana Cipci} for microbiological examina-
tion. The results are a part of the Joint Project »Novel Macro-
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SA@ETAK
3-O-Acilni derivati premo{tenih 15-~lanih azalida: priprava, odre|ivanje strukture
i antibakterijska aktivnost
Andrea Fajdeti}, Gabrijela Kobrehel, Gorjana Lazarevski, Vlado [timac
i Stjepan Mutak
Opisani su priprava, odre|ivanje strukture i biolo{ka ispitivanja 15-~lanih azalida aciliranih na polo`aju C-3.
Kiselom hidrolizom pripadaju}ih 3-kladinozil analoga pripravljeni su 3-dekladinozil-9a,l1-cikli~ki karbamat
9a-aza-9a-homoeritromicina A i njegovi 12-O-alkil derivati. Za{ti}ivanjem 2'-hidroksilne skupine pripravljeni su
po~etni spojevi za aciliranje C-3-hidroksilne skupine. Nakon deprotekcije dobiveni su razni 3-O-acil derivati
~ije su strukture dokazane spektroskopskim metodama (IR, MS, NMR). Novi spojevi ispitani su in vitro na
panelu Gram-pozitivnih i Gram-negativnih bakterija i njihove su aktivnosti uspore|ene s aktivnostima deri-
vata osnovne supstance. 3-O-Acil derivati pokazuju pobolj{anu antibakterijsku aktivnost, ali slabiju od ak-
tivnosti standardnih makrolida.
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